Groningen, Netherlands — EV Biotech, a Dutch synthetic biology company, has announced the launch of ArtemisAI. This proprietary AI platform is set to transform how microbial strains are designed for industrial fermentation.
ArtemisAI combines constraint-based modeling with machine learning. It creates a hybrid system that provides predictive and interpretable insights. Even with limited data, it helps make faster, smarter decisions in microbial engineering and media optimization.
“ArtemisAI doesn’t just optimize biology — it changes the economics of fermentation,” said Linda Dijkshoorn, CEO of EV Biotech. “It models strain performance and production outcomes with minimal data. This opens the door to leaner, more efficient biotech development.”
The platform allows developers to predict the best gene and regulatory targets using small datasets. It can simulate strain performance under different media and process conditions. It also helps prioritize edits that improve fermentation economics.
Unlike traditional AI tools, ArtemisAI was built entirely in-house and was designed for real-world scalability. It supports early-stage development of biobased products, from nutraceuticals to pharmaceuticals.
EV Biotech is seeking partners to co-develop new products using ArtemisAI. Partners will share development costs and access a powerful design engine, reducing risk and speeding up development. EV Biotech will retain rights through licensing, royalties, or joint ventures.
The launch coincides with EV Biotech’s presence at World Bio Markets 2025. The company is connecting with collaborators and investors interested in microbial innovation. With ArtemisAI, EV Biotech aims to accelerate the creation of sustainable, cost-effective bioprocesses. These solutions meet the growing global demand for biobased products.
